Social Sciences · Gender Studies
Tumor Vasculature-Targeted Recombinant Mutated Human TNF-a Enhanced the Antitumor Activity of Doxorubicin by Increasing Tumor Vessel Permeability in Mouse Xenograft Models
Changli Jiang, Junzhou Niu, Meng Li, Yi Teng, Huixuan Wang, Yingqi Zhang
See on the mapAbstract
Objective: Increasing evidence suggests that, when used in combination, tumor necrosis factor-a (TNF-a) synergizes with traditional chemotherapeutic drugs to exert a heightened antitumor effect. The present study investigated the antitumor efficacy of recombinant mutated human TNF-a specifically targeted to the tumor vasculature (RGD-rmhTNF-a) combined with the chemotherapeutic agent doxorubicin in 2 murine allografted tumor models. Methods: Mice bearing hepatoma or sarcoma allografted tumors were treated with various doses of RGD-rmhTNF-a alone or in combination with doxorubicin (2 mg/kg). We then evaluated tumor growth and tumor vessel permeability as well as intratumoral levels of RGD-rmhTNF-a and doxorubicin. Results: RGD-rmhTNF-a treatment enhanced the permeability of the tumor vessels and increased intratumoral doxorubicin levels. In addition, intratumoral RGD-rmhTNF-a levels were significantly higher than that of rmhTNF-a. In both of the tested tumor models, administering RGD-rmhTNF-a in combination with doxorubicin resulted in an enhanced antitumor response compared to either treatment alone. Double-agent combination treatment of doxorubicin with 50,000 IU/kg RGD-rmhTNF-a induced stronger antitumor effects on H22 allografted tumor-bearing mice than the single doxorubicin agent alone. Moreover, doxorubicin with 10,000 IU/kg RGD-rmhTNF-a synergized to inhibit tumor growth in S180 allografted tumor-bearing mice.